NERVGEN PHARMA CORP.(NGEN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
No SEC XBRL data
This company has no XBRL financial filings on file with SEC EDGAR. Common for ADRs, recent IPOs, OTC-listed names, and foreign filers that haven't filed 20-F yet.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NGEN Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for NERVGEN PHARMA CORP. (NGEN), a Healthcare sector company. NGEN is not currently included in 13F Pro's AI-ranked quality universe — this company has no xbrl financial filings on file with sec edgar. common for adrs, recent ipos, otc-listed names, and foreign filers that haven't filed 20-f yet. Top institutional holders of NGEN by reported 13-F value include Empery Asset Management, Rock Springs Capital Management, DAFNA Capital Management, based on the most recent SEC filings. NGEN trades on the Nasdaq exchange and files with the SEC under CIK 1751912. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NERVGEN PHARMA CORP. directly from SEC EDGAR.
Get alerted when NGEN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NERVGEN PHARMA CORP. including:
Top Institutional Holders of NGEN
Empery Asset Management, LP
$8.2M4,000,000 shRock Springs Capital Management LP
$2.5M1,208,231 shDAFNA Capital Management LLC
$2.2M1,050,000 shGhisallo Capital Management LLC
$2.1M1,000,000 shARMISTICE CAPITAL, LLC
$1.4M678,000 shLMR Partners LLP
$1.2M600,000 shMARSHALL WACE, LLP
$898.1K435,962 shUBS Group AG
$782.2K379,726 shStonepine Capital Management, LLC
$740.2K571,678 shJANE STREET GROUP, LLC
$557.7K270,750 sh
| Fund | Value | Shares |
|---|---|---|
| Empery Asset Management, LP | $8.2M | 4,000,000 |
| Rock Springs Capital Management LP | $2.5M | 1,208,231 |
| DAFNA Capital Management LLC | $2.2M | 1,050,000 |
| Ghisallo Capital Management LLC | $2.1M | 1,000,000 |
| ARMISTICE CAPITAL, LLC | $1.4M | 678,000 |
| LMR Partners LLP | $1.2M | 600,000 |
| MARSHALL WACE, LLP | $898.1K | 435,962 |
| UBS Group AG | $782.2K | 379,726 |
| Stonepine Capital Management, LLC | $740.2K | 571,678 |
| JANE STREET GROUP, LLC | $557.7K | 270,750 |
More Healthcare Companies
View all Healthcare →Put NGEN on your watchlist
Track score changes the day NERVGEN PHARMA CORP. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NGEN a good stock to buy?
13F Pro's AI-powered analysis of NERVGEN PHARMA CORP. (NGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NGEN are available on the NGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NGEN is classified as a small company.
Which hedge funds own NGEN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NERVGEN PHARMA CORP.'s investment landscape.